• Acheson DW, Luccioli S 2004 Mucosal immune responses. Best Pract. Res. Clin. Gastroenterol. 18: 387-404.

• Adams RJ, Heazlewood SP, Gilshenan KS, O'Brien M, McGuckin MA, Florin TH 2008 IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin. Am. J. Gastroenterol. 103: 386-396. *

• Al-Eidan FA, McElnay JC, Scott MG, Kearney MP 2000 Clostridium difficile-associated diarrhoea in hospitalised patients. J. Clin. Pharm. Ther. 25: 101-109.

• Albishri SH, Issa S, Kneteman NM, Shapiro AM 2001 Bile leak from duct of Luschka after liver transplantation. Transplantation 72: 338-340.

• Alef K 1999 Clostridium difficile-associated disease. Implications for midwifery practice. J. Nurse Midwifery 44: 19-29.

• Ament ME, Berquist W, Vargas J 1988 Advances in ulcerative colitis. Pediatrician 15: 45-57.

• Ananthakrishnan AN, McGinley EL, Binion DG 2008 Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57: 205-210.

• Araki Y, Andoh A, Takizawa J, Takizawa W, Fujiyama Y 2004 Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int. J. Mol. Med. 13: 577-580.

• Araki Y, Fujiyama Y, Andoh A, Koyama S, Kanauchi O, Bamba T 2000 The dietary combination of germinated barley foodstuff plus Clostridium butyricum suppresses the dextran sulfate sodium-induced experimental colitis in rats. Scand. J. Gastroenterol. 35: 1060-1067. *

• Arends J, Wu J, Borillo J, Troung L, Zhou C, Vigneswaran N, Lou YH 2006 T cell epitope mimicry in antiglomerular basement membrane disease. J. Immunol. 176: 1252-1258. *

• Arnold C, von Sanden S, Theilacker C, Blum HE 2008 Ulcerous colitis and infection with cytomegalovirus, herpes simplex virus and Clostridium difficile. Z. Gastroenterol. 46: 780-783.

• Aslam S, Hamill RJ, Musher DM 2005 Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5: 549-557.

• Balamurugan R, Balaji V, Ramakrishna BS 2008 Estimation of faecal carriage of Clostridium difficile in patients with ulcerative colitis using real time polymerase chain reaction. Indian J. Med. Res. 127: 472-477. *

• Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R 2005 Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 100: 2560-2568. *

• Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R, Petit JC 2007 Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect. Control Hosp. Epidemiol. 28: 131-139.

• Barker HC, Haworth CS, Williams D, Roberts P, Bilton D 2008 Clostridium difficile pancolitis in adults with cystic fibrosis. J. Cyst. Fibros. Jun 26 [Epub ahead of print].

• Barker RH Jr, Dagher R, Davidson DM, Marquis JK 2006 Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment. Pharmacol. Ther. 24: 1525-1534. *

• Batta AK, Tint GS, Xu G, Shefer S, Salen G 1998 Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid. J. Lipid Res. 39: 1641-1646. *

• Beaugerie L, Petit JC 2004 Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract. Res. Clin. Gastroenterol. 18: 337-352.

• Bergert H, Illert T, Friedrich K, Ockert D 2004 Fulminant liver failure following infection by Clostridium perfringens. Surg. Infect. (Larchmt.) 5: 205-209.

• Bergogne-Berezin E 2000 Treatment and prevention of antibiotic associated diarrhea. Int. J. Antimicrob. Agents 16: 521-526.

• Berman L, Carling T, Fitzgerald TN, Bell RL, Duffy AJ, Longo WE, Roberts KE 2008 Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J. Clin. Gastroenterol. 42: 476-480.

• Birnbaum J, Bartlett JG, Gelber AC 2008 Clostridium difficile: an under-recognized cause of reactive arthritis? Clin. Rheumatol. 27: 253-255. *

• Bobak DA 2008 Nitazoxanide to treat persistent Clostridium difficile colitis. Curr. Infect. Dis. Rep. 10: 89-90.

• Bolte ER 1998 Autism and Clostridium tetani. Med. Hypotheses 51: 133-144.

• Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S 2004 Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Gastroenterol. 38: 475-483.

• Bourriaud C, Robins RJ, Martin L, Kozlowski F, Tenailleau E, Cherbut C, Michel C 2005 Lactate is mainly fermented to butyrate by human intestinal microfloras but inter-individual variation is evident. J. Appl. Microbiol. 99: 201-212. *

• Bouza E, Munoz P, Alonso R 2005 Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin. Microbiol. Infect. 11 Suppl. 4: 57-64.

• Bouza E, Pelaez T, Alonso R, Catalan P, Munoz P, Creixems MR 2001 "Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J. Hosp. Infect. 48: 233-237.

• Brar HS, Surawicz CM 2000 Pseudomembranous colitis: an update. Can. J. Gastroenterol. 14: 51-56.

• Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J 2005 Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 1: CD004610. *

• Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D 2001 Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res. Microbiol. 152: 735-741.

• Brown WJ, Hudson MJ, Patrick S, Matthews SC, Hill MJ, Gent AE, Grace RH, Hellier MD, Swarbrick ET 1992 Search for enteric microbial pathogens in patients with ulcerative colitis. Digestion 53: 121-128.

• Cadle RM, Mansouri MD, Darouiche RO 2006 Vancomycin-induced elevation of liver enzyme levels. Ann. Pharmacother. 40: 1186-1189.

• Carson CF, Riley TV 2003 Non-antibiotic therapies for infectious diseases. Commun. Dis. Intell. 27 Suppl.: S143-S146.

• Centers for Disease Control and Prevention (CDC) 2005 Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb. Mortal. Wkly. Rep. 54: 1201-1205.

• Collado MC, Calabuig M, Sanz Y 2007 Differences between the fecal microbiota of coeliac infants and healthy controls. Curr. Issues Intest. Microbiol. 8: 9-14.

• Cottrell GS, Amadesi S, Pikios S, Camerer E, Willardsen JA, Murphy BR, Caughey GH, Wolters PJ, Coughlin SR, Peterson A, Knecht W, Pothoulakis C, Bunnett NW, Grady EF 2007 Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology 132: 2422-2437. *

• Cox KL, Cox KM 1998 Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583.

• Crogan NL, Evans BC 2007 Clostridium difficile: an emerging epidemic in nursing homes. Geriatr. Nurs. 28: 161-164.

• Cucchiara S, Falconieri P, Di Nardo G, Parcelii MA, Dito L, Grandinetti A 2002 New therapeutic approach in the management of intestinal disease: probiotics in intestinal disease in paediatric age. Dig. Liver Dis. 34 Suppl. 2: S44-S47.

• Czerucka D, Piche T, Rampal P 2007 Review article: yeast as probiotics - Saccharomyces boulardii. Aliment. Pharmacol. Ther. 26: 767-778. *

• Davies YK, Cox KM, Abdullah BA, Terry AB, Cox KL 2003 Oral vancomycin: treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 37: 345-346. *

• De Hertogh G, Geboes K 2004 Crohn's disease and infections: a complex relationship. MedGenMed. 6: 14.

• de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A 1992 Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob. Agents Chemother. 36: 2192-2196. *

• Dial S, Delaney JA, Schneider V, Suissa S 2006 Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175: 745-748. *

• Doron S, Gorbach SL 2006 Probiotics: their role in the treatment and prevention of disease. Expert Rev. Anti Infect. Ther. 4: 261-275.

• Duffy M, O'Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP, Kirwan WO 2002 Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis. Colon Rectum 45: 384-388.

• DuPont HL, Garey K, Caeiro JP, Jiang ZD 2008 New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr. Opin. Infect. Dis. 21: 500-507.

• Elsayed S, Zhang K 2006 Isolation and 16S ribosomal RNA gene sequence-based identification of Clostridium scindens from an intra-abdominal abscess. Anaerobe 12: 13-16. *

• Falk A, Olsson C, Ahrne S, Molin G, Adawi D, Jeppsson B 2007 Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens. Scand. J. Gastroenterol. 42: 973-985. *

• Fantry L 2002 Gastrointestinal infections in the immunocompromised host. Curr. Opin. Gastroenterol. 18: 34-39.

• Fedorak RN, Madsen KL 2004 Probiotics and prebiotics in gastrointestinal disorders. Curr. Opin. Gastroenterol. 20: 146-155.

• Fekety R 1997 Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 92: 739-750.

• Fernell E, Fagerberg UL, Hellstrom PM 2007 No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatr. 96: 1076-1079. *

• Fletcher KR, Cinalli M 2007 Identification, optimal management, and infection control measures for Clostridium difficile-associated disease in long-term care. Geriatr. Nurs. 28: 171-181.

• Fordtran JS 2006 Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Proc. Bayl. Univ. Med. Cent. 19: 3-12. *

• Freeman HJ 2008 Recent developments on the role of Clostridium difficile in inflammatory bowel disease. World J. Gastroenterol. 14: 2794-2796. *

• Garcia-Osogobio S, Takahashi T, Gamboa-Dominguez A, Medina H, Arch J, Mass W, Sierra-Madero J, Uscanga L 2000 Toxic pseudomembranous colitis in a patient with ulcerative colitis. Inflamm. Bowel Dis. 6: 188-190. *

• Garner CE, Smith S, de Lacy Costello B, White P, Spencer R, Probert CS, Ratcliffe NM 2007 Volatile organic compounds from feces and their potential for gastrointestinal disease diagnoses. FASEB J. 21: 1675-1688. *

• Gerard L, Garey KW, Dupont HL 2005 Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev. Anti. Infect. Ther. 3: 201-211.

• Gerding DN, Brazier JS 1993 Optimal methods for identifying Clostridium difficile infections. Clin. Infect. Dis. 16 Suppl. 4: S439-S442.

• Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr 1995 Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 16: 459-477.

• Gerding DN, Muto CA, Owens RC Jr 2008 Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46 Suppl. 1: S32-S42.

• Giesemann T, Guttenberg G, Aktories K 2008 Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 134: 2049-2058. *

• Ginsburg PM, Thuluvath PJ 2005 Diarrhea in liver transplant recipients: etiology and management. Liver Transpl. 11: 881-890. *

• Gionchetti P, Rizzello F, Campieri M 2002 Probiotics in gastroenterology. Curr. Opin. Gastroenterol. 18: 235-239.

• Goldin BR, Gorbach SL 2008 Clinical indications for probiotics: an overview. Clin. Infect. Dis. 46 Suppl. 2: S96-S100.

• Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG 2004 Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis. Colon Rectum 47: 1519-1525. *

• Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM 2008 Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 143: 623-629.

• Grossman CJ, Hydo LJ, Wang JC, Pochapin M, Barie PS 2004 Devastating presentations of regional enteritis (Crohn's disease): two reports of survival following severe multiple organ dysfunction syndrome. Surg. Infect. (Larchmt.) 5: 301-307.

• Gursoy S, Guven K, Arikan T, Yurci A, Torun E, Baskol M, Ozbakir O, Yucesoy M 2007 Clostridium difficile infection frequency in patients with nosocomial infections or using antibiotics. Hepatogastroenterology 54: 1720-1724.

• Halsey J 2008 Current and future treatment modalities for Clostridium difficile-associated disease. Am. J. Health Syst. Pharm. 65: 705-715.

• Hartley MG, Hudson MJ, Swarbrick ET, Grace RH, Gent AE, Hellier MD 1996 Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis. Aliment. Pharmacol. Ther. 10: 157-163.

• Huang T, Wei B, Velazquez P, Borneman J, Braun J 2005 Commensal microbiota alter the abundance and TCR responsiveness of splenic naive CD4+ T lymphocytes. Clin. Immunol. 117: 221-230. *

• Inness VL, McCartney AL, Khoo C, Gross KL, Gibson GR 2007 Molecular characterisation of the gut microflora of healthy and inflammatory bowel disease cats using fluorescence in situ hybridisation with special reference to Desulfovibrio spp. J. Anim. Physiol. Anim. Nutr. (Berl.) 91: 48-53. *

• Isono A, Katsuno T, Sato T, Nakagawa T, Kato Y, Sato N, Seo G, Suzuki Y, Saito Y 2007 Clostridium butyricum TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells. Dig. Dis. Sci. 52: 2963-2971. *

• Issa M, Ananthakrishnan AN, Binion DG 2008 Clostridium difficile and inflammatory bowel disease. Inflamm. Bowel Dis. 14: 1432-1442. *

• Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG 2007 Impact of Clostridium difficile on inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5: 345-351.

• Jackisch T, Freitag M, Ludwig K 2006 Gas gangrene with ulcerative colitis under immunosuppressive therapy: report of a case. Zentralbl. Chir. 131: 84-87.

• Janeczko S, Atwater D, Bogel E, Greiter-Wilke A, Gerold A, Baumgart M, Bender H, McDonough PL, McDonough SP, Goldstein R, Simpson KW 2008 The relationship of mucosal bacteria to duodenal histopathology, cytokine mRNA, and clinical disease activity in cats with inflammatory bowel disease. Vet. Microbiol. 128: 178-193. *

• Jiang ZD, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M 2006 A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am. J. Gastroenterol. 101: 1112-1116. *

• Jiang ZD, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, Larocco M, Dupont HL 2007 Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin. Gastroenterol. Hepatol. 5: 964-968.

• Job ML, Jacobs NF Jr 1997 Drug-induced Clostridium difficile-associated disease. Drug Saf. 17: 37-46.

• Johal SS, Hammond J, Solomon K, James PD, Mahida YR 2004 Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 53: 673-677. *

• Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN 1992 Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann. Intern. Med. 117: 297-302.

• Kamiya T, Shikano M, Wada T, Sasaki M, Joh T 2008 The efficacy of probiotics in gastrointestinal disease. Nippon Rinsho 66: 1385-1390.

• Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T 2005 The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr. Pharm. Des. 11: 1047-1053.

• Kanauchi O, Mitsuyama K, Araki Y, Andoh A 2003 Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr. Pharm. Des. 9: 333-346.

• Kang DJ, Ridlon JM, Moore DR 2nd, Barnes S, Hylemon PB 2008 Clostridium scindens baiCD and baiH genes encode stereo-specific 7alpha/7beta-hydroxy-3-oxo-Delta(4)-cholenoic acid oxidoreductases. Biochim. Biophys. Acta 1781: 16-25. *

• Karlinger K, Gyorke T, Mako E, Mester A, Tarjan Z 2000 The epidemiology and the pathogenesis of inflammatory bowel disease. Eur. J. Radiol. 35: 154-167.

• Kelly CP 2007 Protease-activated receptor 2 in the intestinal inflammatory response induced by Clostridium difficile toxin A. Gastroenterology 132: 2599-2601. *

• Kim H, Rhee SH, Pothoulakis C, Lamont JT 2007 Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 133: 875-886. *

• Kleessen B, Kroesen AJ, Buhr HJ, Blaut M 2002 Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand. J. Gastroenterol. 37: 1034-1041.

• Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbrugger RW 2008 The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am. J. Gastroenterol. 103: 178-189. *

• Kotz CM, Peterson LR, Moody JA, Savaiano DA, Levitt MD 1992 Effect of yogurt on clindamycin-induced Clostridium difficile colitis in hamsters. Dig. Dis. Sci. 37: 129-132.

• Kuijper EJ, Coignard B, Tull P; the ESCMID Study Group for Clostridium difficile (ESGCD)*; EU Member States and the European Centre for Disease Prevention and Control (ECDC) 2006 Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12 Suppl. 6: 2-18.

• Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, Papoulis AT, Goddard PJ, Barker RH Jr, Palace GP, Klinger JD 2001 GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob. Agents Chemother. 45: 2340-2347. *

• Kyne L, Kelly CP 2001 Recurrent Clostridium difficile diarrhoea. Gut 49: 152-153. *

• Kyne L, Merry C, O'Connell B, Kelly A, Keane C, O'Neill D 1999 Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 28: 107-113.

• Laffan AM, Bellantoni MF, Greenough WB 3rd, Zenilman JM 2006 Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J. Am. Geriatr. Soc. 54: 1068-1073.

• Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS 2008 Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment. Pharmacol. Ther. Jul 7 [Epub ahead of print]. *

• Leal J, Gregson DB, Ross T, Church DL, Laupland KB 2008 Epidemiology of Clostridium species bacteremia in Calgary, Canada, 2000-2006. J. Infect. 57: 198-203.

• Lee SJ, Qin H, Benveniste EN 2008 The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur. J. Immunol. 38: 2325-2336. *

• Lepercq P, Gerard P, Beguet F, Raibaud P, Grill JP, Relano P, Cayuela C, Juste C 2004 Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by Clostridium baratii isolated from human feces. FEMS Microbiol. Lett. 235: 65-72. *

• Lepercq P, Hermier D, David O, Michelin R, Gibard C, Beguet F, Relano P, Cayuela C, Juste C 2005 Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br. J. Nutr. 93: 457-469. *

• Listrom C, Holt K 2004 Inflammatory bowel disease. Emerg. Med. 36: 24-28.

• Ljungh A, Wadstrom T 2006 Lactic acid bacteria as probiotics. Curr. Issues Intest. Microbiol. 7: 73-89.

• Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ 2007 Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J. Gastrointest. Surg. 11: 138-142. *

• Macdonald IA, Hutchison DM, Forrest TP 1981 Formation of urso- and ursodeoxy-cholic acids from primary bile acids by Clostridium absonum. J. Lipid Res. 22: 458-466. *

• MacDonald IA, Williams CN, Sutherland JD, MacDonald AC 1983 Estimation of ursodeoxycholic acid in human and bear biles using Clostridium absonum 7 beta-hydroxysteroid dehydrogenase. Anal. Biochem. 135: 349-354.

• Maciel AA, Oria RB, Braga-Neto MB, Braga AB, Carvalho EB, Lucena HB, Brito GA, Guerrant RL, Lima AA 2007 Role of retinol in protecting epithelial cell damage induced by Clostridium difficile toxin A. Toxicon. 50: 1027-1040.

• Madsen KL 2001 The use of probiotics in gastrointestinal disease. Can. J. Gastroenterol. 15: 817-822.

• Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN 2000 Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 118: 1094-1105. *

• Maia MR, Chaudhary LC, Figueres L, Wallace RJ 2007 Metabolism of polyunsaturated fatty acids and their toxicity to the microflora of the rumen. Antonie. Van. Leeuwenhoek. 91: 303-314. *

• Makris AT, Gelone S 2007 Clostridium difficile in the long-term care setting. J. Am. Med. Dir. Assoc. 8: 290-299.

• Malamud A, Wilson KT 2000 Treatment of gastrointestinal infections. Curr. Opin. Gastroenterol. 16: 51-55.

• Malnick SD, Zimhony O 2002 Treatment of Clostridium difficile-associated diarrhea. Ann. Pharmacother. 36: 1767-1775.

• Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG 1995 Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann. Intern. Med. 123: 835-840.

• Maroo S, Lamont JT 2006 Recurrent Clostridium difficile. Gastroenterology 130: 1311-1316. *

• Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ 2006 Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm. Bowel Dis. 12: 1136-1145. *

• Mascarenhas MR 2003 Treatment of gastrointestinal problems in cystic fibrosis. Curr. Treat. Options Gastroenterol. 6: 427-441.

• Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T 2000 Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 15: 61-68. *

• Matthews N, Mayberry JF, Rhodes J, Neale L, Munro J, Wensinck F, Lawson GH, Rowland AC, Berkhoff GA, Barthold SW 1980 Agglutinins to bacteria in Crohn's disease. Gut 21: 376-380. *

• McFarland LV 2008 Update on the changing epidemiology of Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 40-48. *

• McFarland LV 2006 Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101: 812-822. *

• McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN 1999 Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20: 43-50.

• McVey DC, Vigna SR 2005 The role of leukotriene B4 in Clostridium difficile toxin A-induced ileitis in rats. Gastroenterology 128: 1306-1316. *

• Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA 2004 The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J. Clin. Gastroenterol. 38: 772-775.

• Miller C, Florman S, Kim-Schluger L, Lento P, De La Garza J, Wu J, Xie B, Zhang W, Bottone E, Zhang D, Schwartz M 2004 Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl. 10: 1315-1319. *

• Miner J, Gillan MM, Alex P, Centola M 2005 Steroid-refractory ulcerative colitis treated with corticosteroids, metronidazole and vancomycin: a case report. BMC Gastroenterol. 5: 3. *

• Moawad F, Truesdell A, Mulhall B 2006 A "fishy" cough: hepatobronchial fistula due to a pyogenic liver abscess. N. Z. Med. J. 119: U1906.

• Monaghan T, Boswell T, Mahida YR 2008 Recent advances in Clostridium difficile-associated disease. Gut 57: 850-860.

• Morimoto Y, Nomura K, Tsutsumi Y, Ohshiro M, Fujimoto Y, Shimizu D, Wakabayashi N, Konishi H, Mitsufuji S, Matsumoto Y, Taniwaki M 2008 Clostridium difficile-associated diarrhea with hematochezia is associated with ulcer formation. Scand. J. Gastroenterol. Mar 6 [Epub ahead of print]. *

• Morinville V, McDonald J 2005 Clostridium difficile-associated diarrhea in 200 Canadian children. Can. J. Gastroenterol. 19: 497-501.

• Moss AC, Anton P, Savidge T, Newman P, Cheifetz AS, Gay J, Paraschos S, Winter MW, Moyer MP, Karalis K, Kokkotou E, Pothoulakis C 2007 Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut 56: 1210-1217. *

• Moyenuddin M, Williamson JC, Ohl CA 2002 Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy. Curr. Gastroenterol. Rep. 4: 279-286.

• Moyer MS, Graeme-Cook FM 2002 Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2002. A 17-year-old boy with biliary obstruction. N. Engl. J. Med. 346: 271-276.

• Musher DM, Nuila F, Logan N 2007 The long-term outcome of treatment of Clostridium difficile colitis. Clin. Infect. Dis. 45: 523-524.

• Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS 2004 Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur. J. Gastroenterol. Hepatol. 16: 775-778.

• Mylonakis E, Ryan ET, Calderwood SB 2001 Clostridium difficile-associated diarrhea: a review. Arch. Intern. Med. 161: 525-533. *

• Na X, Zhao D, Koon HW, Kim H, Husmark J, Moyer MP, Pothoulakis C, Lamont JT 2005 Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology 128: 1002-1011. *

• Nadal I, Donant E, Ribes-Koninckx C, Calabuig M, Sanz Y 2007 Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J. Med. Microbiol. 56: 1669-1674. *

• Nambiar PR, Kirchain SM, Courmier K, Xu S, Taylor NS, Theve EJ, Patterson MM, Fox JG 2006 Progressive proliferative and dysplastic typhlocolitis in aging Syrian hamsters naturally infected with Helicobacter spp.: a spontaneous model of inflammatory bowel disease. Vet. Pathol. 43: 2-14. *

• Nayar DM, Vetrivel S, McElroy J, Pai P, Koerner RJ 2006 Toxic megacolon complicating Escherichia coli O157 infection. J. Infect. 52: e103-e106.

• Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC 2008 Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis. Jul 14 [Epub ahead of print]. *

• Nguyen GC, Kaplan GG, Harris ML, Brant SR 2008 A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 103: 1443-1450. *

• Nomura K, Fujimoto Y, Yamashita M, Morimoto Y, Ohshiro M, Sato K, Oyake T, Kowata S, Konishi H, Yoshikawa T, Ishida Y, Taniwaki M 2008 Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand. J. Gastroenterol. Sep 9 [Epub ahead of print]. *

• Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, Benno Y, Hirai S, Hojo M, Kobayashi O, Terai T, Miwa H, Takei Y, Ogihara T, Sato N 2005 Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment. Pharmacol. Ther. 21: 1017-1027. *

• Oda M, Kihara A, Yoshioka H, Saito Y, Watanabe N, Uoo K, Higashihara M, Nagahama M, Koide N, Yokochi T, Sakurai J 2008 Effect of erythromycin on biological activities induced by Clostridium perfringens alpha-toxin. J. Pharmacol. Exp. Ther. Sep 15 [Epub ahead of print]. *

• Owens RC 2007 Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs 67: 487-502.

• Park SS, Lillehoj HS, Allen PC, Park DW, FitzCoy S, Bautista DA, Lillehoje EP 2008 Immunopathology and cytokine responses in broiler chickens coinfected with Eimeria maxima and Clostridium perfringens with the use of an animal model of necrotic enteritis. Avian Dis. 52: 14-22.

• Pechine S, Janoir C, Collignon A 2005 Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J. Clin. Microbiol. 43: 5018-5025. *

• Penner R, Fedorak RN, Madsen KL 2005 Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr. Opin. Pharmacol. 5: 596-603.

• Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D 2004 Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171: 466-472. *

• Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I 2007 Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol. 102: 2781-2788. *

• Pham M, Lemberg DA, Day AS 2008 Probiotics: sorting the evidence from the myths. Med. J. Aust. 188: 304-308. *

• Phillips C 2001 Serum antibody responses to Clostridium difficile toxin A: predictive and protective? Gut 49: 167-168. *

• Pituch H, Obuch-Woszczatynski P, Glinka D, Lazinska B, Meisel-Mikolajczyk F, Luczak M 2003 Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002. Med. Dosw. Mikrobiol. 55: 253-258.

• Pochapin M 2000 The effect of probiotics on Clostridium difficile diarrhea. Am. J. Gastroenterol. 95: S11-S13.

• Powell N, Jung SE, Krishnan B 2008 Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent? Gut 57: 1183-1184.

• Prindiville T, Cantrell M, Wilson KH 2004 Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn's disease. Inflamm. Bowel Dis. 10: 824-833. *

• Probert CS, Jones PR, Ratcliffe NM 2004 A novel method for rapidly diagnosing the causes of diarrhoea. Gut 53: 58-61. *

• Pulverer G, Ko HL, Roszkowski W, Beuth J, Yassin A, Jeljaszewicz J 1990 Digestive tract microflora liberates low molecular weight peptides with immunotriggering activity. Zentralbl. Bakteriol. 272: 318-327.

• Quigley EM 2007 Probiotics in the management of colonic disorders. Curr. Gastroenterol. Rep. 9: 434-440.

• Rea MC, Clayton E, O'connor PM, Shanahan F, Kiely B, Ross RP, Hill C 2007 Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J. Med. Microbiol. 56: 940-946. *

• Reinke CM, Messick CR 1994 Update on Clostridium difficile-induced colitis, Part 2. Am. J. Hosp. Pharm. 51: 1892-1901.

• Reinke CM, Messick CR 1994 Update on Clostridium difficile-induced colitis, Part 1. Am. J. Hosp. Pharm. 51: 1771-1781.

• Rhee KJ, Sethupathi P, Driks A, Lanning DK, Knight KL 2004 Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J. Immunol. 172: 1118-1124. *

• Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN 2007 Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch. Surg. 142: 624-631.

• Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD 2007 Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5: 339-344.

• Rolfe RD 2000 The role of probiotic cultures in the control of gastrointestinal health. J. Nutr. 130: 396S-402S. *

• Rooney AP, Swezey JL, Friedman R, Hecht DW, Maddox CW 2006 Analysis of core housekeeping and virulence genes reveals cryptic lineages of Clostridium perfringens that are associated with distinct disease presentations. Genetics 172: 2081-2092. *

• Rossel P, Sortsoe Jensen H, Qvist P, Arveschoug A 1999 Prognosis of adult-onset idiopathic bile acid malabsorption. Scand. J. Gastroenterol. 34: 587-590. *

• Sadighi Akha AA, Berger SB, Miller RA 2006 Enhancement of CD8 T-cell function through modifying surface glycoproteins in young and old mice. Immunology 119: 187-194. *

• Sandberg-Gertzen H, Kjellander J, Sundberg-Gilla B, Jarnerot G 1985 In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria. Scand. J. Gastroenterol. 20: 607-612.

• Sartor RB 2001 Induction of mucosal immune responses by bacteria and bacterial components. Curr. Opin. Gastroenterol. 17: 555-561.

• Savoye G 2008 alpha-Defensins and Clostridium difficile. Recent growing concerns in inflammatory bowel disease. Am. J. Gastroenterol. Sep 4 [Epub ahead of print]. *

• Scarpignato C, Pelosini I 2005 Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51 Suppl. 1: 36-66.

• Schroeder MS 2005 Clostridium difficile-associated diarrhea. Am. Fam. Physician 71: 921-928. *

• Seo DH, Stone CD 2008 More bad news on Clostridium difficile in inflammatory bowel disease. Inflamm. Bowel Dis. Sep 11 [Epub ahead of print].

• Shah SB, Hanauer SB 2007 Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev. Gastroenterol. Disord. 7 Suppl. 3: S3-S10.

• Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW 2006 Clostridium difficile-associated pouchitis. Dig. Dis. Sci. 51: 2361-2364. *

• Shen BO, Jiang ZD, Fazio VW, Remzi FH, Rodriguez L, Bennett AE, Lopez R, Queener E, Dupont HL 2008 Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin. Gastroenterol. Hepatol. 6: 782-788.

• Siegal D, Syed F, Hamid N, Cunha BA 2005 Campylobacter jejuni pancolitis mimicking idiopathic ulcerative colitis. Heart Lung 34: 288-290.

• Smith FM, Coffey JC, Kell MR, O'sullivan M, Redmond HP, Kirwan WO 2005 A characterization of anaerobic colonization and associated mucosal adaptations in the undiseased ileal pouch. Colorectal Dis. 7: 563-570. *

• Sohi S, Cohen RD 2006 Management of refractory ulcerative colitis. Curr. Treat. Options Gastroenterol. 9: 234-245.

• Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Dore J 2006 Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm. Bowel Dis. 12: 106-111. *

• Solis DR, Hemming AW, Reed A, Van der Werf WJ, Fujita S, Howard RJ 2004 Clostridial infection in a liver transplant recipient. Clin. Transplant. 18: 726-728. *

• Sougioultzis S Pothoulakis C 2003 Bacterial infections: small intestine and colon. Curr. Opin. Gastroenterol. 19: 23-30.

• Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP 2005 Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128: 764-770. *

• Stepan C, Surawicz CM 2007 Treatment strategies for C. difficile associated diarrhea. Acta Gastroenterol. Latinoam. 37: 183-191.

• Stone CD 2008 Prognosis in Clostridium difficile infection complicating inflammatory bowel disease. Gut 57: 150-152.

• Sullivan A, Nord CE 2005 Probiotics and gastrointestinal diseases. J. Intern. Med. 257: 78-92. *

• Sunenshine RH, McDonald LC 2006 Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve. Clin. J. Med. 73: 187-197. *

• Surawicz C 2006 Clostridium difficile infection. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 46-49. *

• Surawicz CM 2004 Treatment of recurrent Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 32-38. *

• Surawicz CM 1998 Clostridium difficile disease: diagnosis and treatment. Gastroenterologist 6: 60-65.

• Surawicz CM, McFarland LV 1999 Pseudomembranous colitis: causes and cures. Digestion 60: 91-100.

• Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE 2006 Past, present, and future therapies for Clostridium difficile-associated disease. Ann. Pharmacother. 40: 2155-2163.

• Sutherland JD, Macdonald IA, Forrest TP 1982 The enzymic and chemical synthesis of ursodeoxycholic and chenodeoxycholic acid from cholic acid. Prep. Biochem. 12: 307-321.

• Sutton PA, Li S, Webb J, Solomon K, Brazier J, Mahida YR 2008 Essential role of toxin A in C. difficile 027 and reference strain supernatant-mediated disruption of Caco-2 intestinal epithelial barrier function. Clin. Exp. Immunol. May 26 [Epub ahead of print].

• Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H 2005 Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43: 3380-3389. *

• Sydora BC, Tavernini MM, Doyle JS, Fedorak RN 2005 Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response. Dig. Dis. Sci. 50: 905-913. *

• Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T 2008 Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int. J. Med. Microbiol. 298: 463-472.

• Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT Jr 1983 Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2: 1043-1046.

• Thukral C, Travassos WJ, Peppercorn MA 2005 The role of antibiotics in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 8: 223-228.

• Titball RW, Naylor CE, Basak AK 1999 The Clostridium perfringens alpha-toxin. Anaerobe 5: 51-64.

• Tremaine WJ 2007 Inflammatory bowel disease and Clostridium difficile-associated diarrhea: a growing problem. Clin. Gastroenterol. Hepatol. 5: 310-311.

• Tsironi E, Irving PM, Feakins RM, Rampton DS 2006 "Diversion" colitis caused by Clostridium difficile infection: report of a case. Dis. Colon Rectum 49: 1074-1077. *

• Uzal FA, Fisher DJ, Saputo J, Sayeed S, McClane BA, Songer G, Trinh HT, Fernandez Miyakawa ME, Gard S 2008 Ulcerative enterocolitis in two goats associated with enterotoxin- and beta2 toxin-positive Clostridium perfringens type D. J. Vet. Diagn. Invest. 20: 668-672.

• Van Itallie CM, Betts L, Smedley JG 3rd, McClane BA, Anderson JM 2008 Structure of the claudin-binding domain of Clostridium perfringens enterotoxin. J. Biol. Chem. 283: 268-274. *

• Vanjak D, Girault G, Branger C, Rufat P, Valla DC, Fantin B 2007 Risk factors for Clostridium difficile infection in a hepatology ward. Infect. Control Hosp. Epidemiol. 28: 202-204.

• Vasquez N, Mangin I, Lepage P, Seksik P, Duong JP, Blum S, Schiffrin E, Suau A, Allez M, Vernier G, Treton X, Dore J, Marteau P, Pochart P 2007 Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresis. Inflamm. Bowel Dis. 13: 684-692. *

• Viswanathan VK, Sharma R, Hecht G 2004 Microbes and their products: physiological effects upon mammalian mucosa. Adv. Drug Deliv. Rev. 56: 727-762. *

• Wanahita A, Davis B, Hamill RJ, Goldsmith EA, Rodgers JR, Cook RG, Lamphear JG, Musher DM 2006 Clostridium difficile lacks detectable superantigen activity. FEMS Immunol. Med. Microbiol. 47: 275-277. *

• Warchol M, Car L, Grill JP, Schneider F 2003 Metabolic changes in Clostridium absonum ATCC 27555 accompanying induction of epimerization of a primary bile acid. Curr. Microbiol. 47: 425-430.

• Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC 2005 Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084. *

• Watanakunakorn C 1984 Mode of action and in-vitro activity of vancomycin. J. Antimicrob. Chemother. 14 Suppl. D: 7-18.

• Weber P, Koch M, Heizmann WR, Scheurlen M, Jenss H, Hartmann F 1992 Microbic superinfection in relapse of inflammatory bowel disease. J. Clin. Gastroenterol. 14: 302-308.

• Weissbach H 2008 The isolation of the vitamin B12 coenzyme and the role of the vitamin in methionine synthesis. J. Biol. Chem. 283: 23497-23504. *

• Wilcox MH, Howe R 1995 Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J. Antimicrob. Chemother. 36: 673-679.

• Wullt M, Johansson Hagslatt ML, Odenholt I, Berggren A 2007 Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent Clostridium difficile-associated diarrhea. Dig. Dis. Sci. 52: 2082-2086. *

• Wuorela M, Raiha I 2000 Acute haemorrhagic colitis possibly caused by Clostridium perfringens. Scand. J. Gastroenterol. 35: 559-560. *

• Yahav J, Samra Z, Blau H, Dinari G, Chodick G, Shmuely H 2006 Helicobacter pylori and Clostridium difficile in cystic fibrosis patients. Dig. Dis. Sci. 51: 2274-2279. *

• Ye J, Lee JW, Presley LL, Bent E, Wei B, Braun J, Schiller NL, Straus DS, Borneman J 2008 Bacteria and bacterial rRNA genes associated with the development of colitis in IL-10(-/-) mice. Inflamm. Bowel Dis. 14: 1041-1050. *

• Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC 2006 Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment. Pharmacol. Ther. 24: 613-619. *

• Zhang M, Liu B, Zhang Y, Wei H, Lei Y, Zhao L 2007 Structural shifts of mucosa-associated Lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J. Clin. Microbiol. 45: 496-500. *

Number of references = 228

www psc-literature.org